Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana (ACTIPT)

The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana

The purpose of this study is to determine if Artemisinin-based Combination Therapy, ACT,(artemether-lumefantrine) used as intermittent preventive treatment (IPT) alone or in combination with praziquantel, will have any effects on anemia, malaria, schistosomiasis and school sustained attention and concentration.

Study Overview

• Status: Unknown
• Conditions: Anemia; Malaria; Helminthiasis; Schistosomiasis; Change in Sustained Attention
• Intervention / Treatment: Drug: Artemether-lumefantrine combination plus albendazole; Drug: Artemether-lumefantrine plus Praziquantel plus Albendazole; Drug: Albendazole plus Praziquantel

Detailed Description

Introduction: Malaria, schistosomiasis and soil-transmitted helminth (STH) infections are rife in sub-Saharan Africa where school children are at great risk of morbidity. Although the strategy of using intermittent preventive treatment (IPT) for malaria control has been proven beneficial among infants and pregnant women, it is yet to be implemented in school children on a large scale. Sulfadoxine-pyrimethamine (SP) use as IPT is being limited by widespread reports of resistance. Artemisinin-based combination therapy (ACT) has been proven efficacious as IPT among school children in few studies. Other studies have shown that artemisinin derivatives exhibit anti-schistosomal activity. This could be an added effect of using ACTs, as IPT, to prevent malaria related morbidity in school children in sub-Saharan Africa.

General Objective: To examine the effect of IPT with ACTs and anti-helminthes against malaria and helminthes infections on health and school attention among children 6 to 12 years old.

Specific objectives

1. To estimate the prevalence of malaria parasitemia, schistosomiasis and anemia among primary schoolchildren.
2. To determine the impact of 3 doses of IPT (with artemether-lumefantrine) and de-worming (with albendazole and/or praziquantel) on hemoglobin and school (classroom) attention and recall.
3. To determine the effects of IPT (with artemether-lumefantrine) and de-worming (with albendazole and /or praziquantel) on the prevalence and intensity of schistosomes infection among schoolchildren.
4. To determine the safety and tolerability of IPT with artemether-lumefantrine combined with albendazole and/or praziquantel among school children.

Materials and methods: An open-labeled randomized trial, including 3 arms, will be carried out in 6 primary schools in the Kassena-Nankana Districts, Ghana, where malaria and schistosome infection (with S. hematobium and S. mansoni) are endemic. After informed consent and assent are obtained, about 345 (115 in each arm) class three school children will be investigated for malaria parasitemia, anemia, schistosome and soil-transmitted helminths infections, and classroom attention and recall in a baseline pre-intervention survey. Mass treatment is then carried out in the 6 randomized schools with ACT and albendazole in one study arm; ACT, albendazole and praziquantel in the second arm while albendazole and praziquantel will be given in the third school arm. ACT mass treatment using artemether-lumefantrine is carried out every school term (4 monthly) for one year while praziquantel is given once and albendazole twice a year. After one academic year, the same 345 (115 in each arm) selected participants in class three are assessed for hemoglobin, malaria parasitemia, STH and schistosome infections and classroom attention and recall. Safety and tolerability of the combined IPT is assessed at 28 days post treatment.

Data analysis- Data will be analyzed by both intention-to-treat and per-protocol employing uni-variate and multivariate logistic regression analysis.

• Study Type: Interventional
• Enrollment (Anticipated): 345
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Ernest C Opoku, MD, MPH; Phone Number: +233 244 734608; Email: erniecudjoe@yahoo.com
• Study Contact Backup: Name: Abraham V Hodgson, MD, MPH, PhD; Phone Number: +233 244 577665; Email: AHodgson@navrongo.mimcom.net

Study Locations

• Ghana
  • Navrongo, Ghana
    • Recruiting
    • NHRC
    • Contact: Ernest C Opoku, MD, MPH; Phone Number: +233 244 734608; Email: erniecudjoe@yahoo.com
    • Contact: Abraham V Hodgson, MD, MPH, PhD; Phone Number: +233 244 577665; Email: AHodgson@navrongo.mimcom.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 12 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Parental informed consent and assent by schoolchildren
• No known history of allergy to any study drug
• Aged 6 or more years

Exclusion Criteria:

• lack of parental informed consent and assent by schoolchildren
• Known allergy or history of allergy to any study drug
• Aged less than 6 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AL plus ABZ; Arm 1; Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral	Drug: Artemether-lumefantrine combination plus albendazole; AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
Active Comparator: AL plus PZQ plus ABZ; Arm 2; artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral	Drug: Artemether-lumefantrine plus Praziquantel plus Albendazole; Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
Active Comparator: ABZ plus PZQ; Arm 3; Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral	Drug: Albendazole plus Praziquantel; Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence and density of malaria parasites, determined by microscopy, as a measure of efficacy	Change from baseline of prevalence and density of malaria parasitemia 28 days post interventions	Day 28 post intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events as a measure of safety and tolerability	Number of reported adverse events within twelve months of intervention per study arm	Day 365
Number of schoolchildren with sustained attention and recall as a measure of efficacy	Change in sustained classroom attention and recall in 365 days of start of intervention from baseline	Day 365
Proportion of schoolchildren with anemia as a measure of safety and tolerability	Proportion of schoolchildren having hemoglobin level less than 12.0g/dl from baseline level in 365 days of start of intervention	Day 365
Prevalence and intensity of urinary schistosomiasis as a measure of efficacy	Proportion of schoolchildren with urinary schistosomiasis by study arm compared to baseline	365 days post first intervention
Prevalence and density of malaria parasites by microscopy as a measure of efficacy	Proportion of schoolchildren with malaria parasitemia by study arm compared to baseline	365 days
Prevalence and intensity of intestinal schistosomiasis among schoolchildren as a measure of efficacy	Proportion of schoolchildren with intestinal schistosomiasis by study arm compared to baseline	365 days

Collaborators and Investigators

• Sponsor: Navrongo Health Research Centre, Ghana
• Collaborators: DBL -Institute for Health Research and Development
• Investigators: Principal Investigator: Ernest C Opoku, MD, MPH, Navrongo Health Research Centre, Ghana; Principal Investigator: Pascal Magnussen, MD, University of Copenhagen; Study Director: Abraham V Hodgson, MD, MPH, PhD, Navrongo Health Research Centre, Ghana; Principal Investigator: Edmund L Browne, MD, MPH, PhD, University of Development Studies; Principal Investigator: Annette Olsen, PhD, University of Copenhagen

Study record dates

Study Major Dates

• Study Start: December 1, 2010
• Primary Completion (Anticipated): October 1, 2011
• Study Completion (Anticipated): November 1, 2012

Study Registration Dates

• First Submitted: October 17, 2011
• First Submitted That Met QC Criteria: October 22, 2011
• First Posted (Estimate): October 25, 2011

Study Record Updates

• Last Update Posted (Estimate): October 25, 2011
• Last Update Submitted That Met QC Criteria: October 22, 2011
• Last Verified: October 1, 2011

More Information

Terms related to this study

• Keywords: Anemia; Hemoglobin; malaria; Schoolchildren; ACT; IPT; schistosomiasis; Recall; Sustained attention; Kassena-Nankana
• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Trematode Infections; Malaria; Helminthiasis; Schistosomiasis; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antiprotozoal Agents; Antiparasitic Agents; Antimalarials; Anthelmintics; Antiplatyhelmintic Agents; Anticestodal Agents; Lumefantrine; Artemether; Artemether, Lumefantrine Drug Combination; Albendazole; Praziquantel
• Other Study ID Numbers: NHRCIRB098